SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) – Acepodia, a biotechnology firm growing cell therapies for next-generation stable tumors and hematologic most cancers, right now introduced the closing of its $ 47 million Sequence B funding. {dollars}. The funding will probably be used to advance the corporate’s flagship Pure Killer (NK) cell remedy candidate, ACE1702, by way of scientific improvement in stable tumors, and to advance its preclinical NK cell and gamma delta remedy pipeline. T within the clinic. Acepodia plans to finish IND research for 2 extra pipeline merchandise in 2021.

The funding spherical was supported by new US institutional traders together with Ridgeback Capital Investments, 8VC and DEFTA Companions, and Taiwan-based institutional investor CDIB Capital Healthcare. Acepodia’s Sequence A traders additionally participated.

“This second capital improve for Acepodia represents a powerful vote of confidence from our traders in our extremely differentiated strategy to cell remedy, notably with NK cells, and within the firm’s potential to offer superior remedy choices for them. most cancers sufferers, ”stated Sonny Hsiao, Ph.D., founder and CEO of Acepodia. “Accessible and efficient commercially obtainable allogeneic cell therapies will probably be an necessary element of subsequent technology most cancers remedy. With our self-discipline and capital effectivity, we’re properly positioned to attain our company objectives, together with the continued scientific improvement of those therapies, together with our lead candidate, ACE1702 for the remedy of stable tumors, and the execution of future scientific trials for our promising preclinical portfolio of candidates for NK and NK sort gamma delta T cell remedy. “

Wayne Holman, MD, CEO and Founding father of Ridgeback Capital, added, “We’re delighted to take part on this funding for Acepodia as a result of we consider within the elementary proof suggesting that cell therapies ought to play an necessary function in the way forward for most cancers remedy. . We consider that the earlier success of Acepodia’s main group in cell therapies and distinctive antibody-cell conjugation (ACC) expertise when utilized to commercially obtainable cryopreserved allogeneic NK cells might result in improved outcomes and differentiated.

Acepodia’s expertise permits the event of cell therapies with improved tumor engagement and concentrating on by way of optimized cell receptor choice and clear conjugation with antibody therapies. Utilizing its proprietary, patented Antibody-Cell Conjugation (ACC) expertise, Acepodia is ready to straight conjugate and arm NK or gamma delta T cells with anti-tumor antibodies validated for cell remedy, a design that has demonstrated its effectiveness. capability to historically overcome resilient tumor defenses in preclinical trials. The corporate is presently conducting an ongoing Part 1 scientific trial of ACE1702, the primary NK cell conjugated antibody remedy in scientific improvement for the remedy of stable tumors expressing HER2.

About Acepodia

Acepodia is a privately held biotechnology firm centered on eradicating cancers of all kinds by way of highly effective, focused cell therapies of the best order. The corporate’s next-generation allogeneic (NK) allogeneic cell therapies are primarily based on a proprietary NK cell line (oNK) which was chosen for its potent anti-tumor exercise. This cell line is additional enhanced by the proprietary ACC (Antibody-Cell Conjugation) expertise which hyperlinks tumor-targeting antibodies to ONK cell floor proteins to direct and maximize tumor cell destruction. The Firm’s lead product candidate, ACE1702, is an antibody-conjugated NK cell remedy in scientific improvement at a number of US most cancers facilities for the remedy of stable tumors expressing HER2. For extra data go to https://www.acepodia.com.

Contact Acepodia
Spike Lo, Senior Director of Enterprise Improvement
Acepodia
886 (2) 2697-6100
[email protected]

Investor contact
Sylvia Wheeler
Wheelhouse Life Science Consultants
[email protected]

Media contact
Michael tattory
LifeSci Communications
1 (646) 751-4362
[email protected]